US Tariffs Fatal for European Pharma

Under the trade agreement concluded between the European Union and the United States at the end of July, exports of pharmaceutical products from Europe to the US will also be subject to a 15% tariff in future. For imports from Switzerland—not a member of the EU—the US Administration has even announced a 39% tariff. And for most goods from the UK, tariffs of 10% have been set. Although pharmaceutical products are still exempt from this, significant levies are also looming here. Companies and associations see this as a break with previous practice and expect significant economic losses. How is the industry responding to the new challenges?